ANHYDROUS MANGAFODIPIR TRISODIUM clinical trials

A Phase 2 Proof-of-Concept clinical trial to quantify myocardial manganese uptake rate by cardiovascular magnetic resonance imaging following mangafodipir trisodium administration in healthy volunteers and heart failure patients with preserved ejection fraction caused by hypertrophic cardiomyopathy or cardiac amyloidosis.

This study looks at how a special scan can show how much manganese goes into the heart, comparing healthy people with those who have heart failure due to specific conditions. The aim is to see if this method can help us understand these heart problems better.